Elisabet Llonch

Elisabet Llonch

Auto-generated profile, based on publicly available information

Elisabet Llonch

Institute for Research in Biomedicine, The Barcelona Institute of Science and Technology, 08028 Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JVJessica Vitos-Faleato
Jessica Vitos-Faleato
SRSebastián Real
Sebastián Real
NGNuria Gutierrez-Prat
Nuria Gutierrez-Prat
AVAlberto Villanueva
Alberto Villanueva
ELElisabet Llonch
Elisabet Llonch
Angel R. NebredaAngel R. Nebreda
Angel R. Nebreda
Malignant transformation entails important changes in the control of cell proliferation through the rewiring of selected signaling pathways. Cancer cells then become very dependent on the proper function of those pathways, and their inhibition offers therapeutic opportunities. Here we identify the stress kinase p38α as a nononcogenic signaling molecule that enables the progression of KrasG12V-driven lung cancer. We demonstrate in vivo that, despite acting as a tumor suppressor in healthy alveolar progenitor cells, p38α contributes to the proliferation and malignization of lung cancer epithelial cells. We show that high expression levels of p38α correlate with poor survival in lung adenocarcinoma patients, and that genetic or chemical inhibition of p38α halts tumor growth in lung cancer mouse models. Moreover, we reveal a lung cancer epithelial cell-autonomous function for p38α promoting the expression of TIMP-1, which in turn stimulates cell proliferation in an autocrine manner. Altogether, our results suggest that epithelial p38α promotes KrasG12V-driven lung cancer progression via maintenance of cellular self-growth stimulatory signals. Significance Nearly half of the cases of lung cancer bear mutations in the RAS pathway. Unfortunately, no specific drugs are available to successfully target many RAS-driven tumors that are not surgically resectable. Despite the sound rationale for targeting oncogene products for cancer therapeutics, this often leads to development of resistance. As an alternative, nononcogenic proteins can sometimes facilitate tumor progression, and, even though they are neither mutated nor overexpressed in the malignant cells, they may represent potential targets for anticancer therapies. We have found that nononcogenic signaling through p38α plays a tumor-promoting function in lung adenocarcinoma epithelial cells by inducing the expression of TIMP-1, a growth factor-like protein. We propose that p38α inhibition could be therapeutically useful.

16 July 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NGNuria Gutierrez-Prat
Nuria Gutierrez-Prat
MCMonica Cubillos-Rojas
Monica Cubillos-Rojas
BCBegoña Cánovas
Begoña Cánovas
AKAntonija Kuzmanic
Antonija Kuzmanic
JGJalaj Gupta
Jalaj Gupta
Angel R. NebredaAngel R. Nebreda
Angel R. Nebreda
Significance: In response to stress, cells can activate several mechanisms that support functionality and survival. However, strong or persistent stresses usually trigger a deleterious answer that leads to cell death. The protein kinases p38α and MK2 are implicated in a stress-signaling pathway. Here, we characterize a molecular mechanism that helps to translate the stress-induced activation of the p38α–MK2 pathway into appropriate biological responses. We show that MK2-expression levels are regulated by the stress intensity and that degradation of MK2 triggered by ubiquitination is linked to cell death. This mechanism will be valuable to better understand the implication of this signaling pathway in pathologies such as inflammatory diseases and cancer.